IL165022A0 - Formulations containing amiodarone and sulfoalkyl ether cyclodextrin - Google Patents
Formulations containing amiodarone and sulfoalkyl ether cyclodextrinInfo
- Publication number
- IL165022A0 IL165022A0 IL16502203A IL16502203A IL165022A0 IL 165022 A0 IL165022 A0 IL 165022A0 IL 16502203 A IL16502203 A IL 16502203A IL 16502203 A IL16502203 A IL 16502203A IL 165022 A0 IL165022 A0 IL 165022A0
- Authority
- IL
- Israel
- Prior art keywords
- formulations containing
- sulfoalkyl ether
- ether cyclodextrin
- containing amiodarone
- amiodarone
- Prior art date
Links
- IYIKLHRQXLHMJQ-UHFFFAOYSA-N amiodarone Chemical compound CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCCN(CC)CC)C(I)=C1 IYIKLHRQXLHMJQ-UHFFFAOYSA-N 0.000 title abstract 2
- 229960005260 amiodarone Drugs 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 title 2
- 229920000858 Cyclodextrin Polymers 0.000 title 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 title 1
- 125000004964 sulfoalkyl group Chemical group 0.000 title 1
- 208000020446 Cardiac disease Diseases 0.000 abstract 1
- 208000019622 heart disease Diseases 0.000 abstract 1
- 239000012669 liquid formulation Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0006—Skin tests, e.g. intradermal testing, test strips, delayed hypersensitivity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Nanotechnology (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Medical Informatics (AREA)
- Toxicology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/139,620 US6869939B2 (en) | 2002-05-04 | 2002-05-04 | Formulations containing amiodarone and sulfoalkyl ether cyclodextrin |
| PCT/US2003/013250 WO2003092590A2 (en) | 2002-05-04 | 2003-04-29 | Formulations containing amiodarone and sulfoalkyl ether cyclodextrin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL165022A0 true IL165022A0 (en) | 2005-12-18 |
Family
ID=29399340
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL16502203A IL165022A0 (en) | 2002-05-04 | 2003-04-29 | Formulations containing amiodarone and sulfoalkyl ether cyclodextrin |
| IL165022A IL165022A (en) | 2002-05-04 | 2004-11-04 | Formulations containing amiodarone and sulfoalkyl ether cyclodextrin |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL165022A IL165022A (en) | 2002-05-04 | 2004-11-04 | Formulations containing amiodarone and sulfoalkyl ether cyclodextrin |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US6869939B2 (ko) |
| EP (2) | EP2402008B1 (ko) |
| JP (2) | JP4764004B2 (ko) |
| KR (1) | KR100984197B1 (ko) |
| AT (1) | ATE535239T1 (ko) |
| AU (1) | AU2003234285B2 (ko) |
| CA (1) | CA2483774C (ko) |
| CY (1) | CY1112527T1 (ko) |
| DK (2) | DK2402008T3 (ko) |
| ES (2) | ES2378306T3 (ko) |
| HU (1) | HUE027551T2 (ko) |
| IL (2) | IL165022A0 (ko) |
| MX (1) | MXPA04010925A (ko) |
| PT (1) | PT1501496E (ko) |
| SI (2) | SI1501496T1 (ko) |
| WO (1) | WO2003092590A2 (ko) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005082416A2 (en) | 2004-01-30 | 2005-09-09 | Pfizer Products Inc. | Antimicrobial preservatives to achieve multi-dose formulation using beta-cyclodextrins for liquid dosage forms |
| RU2006141358A (ru) | 2004-04-23 | 2008-05-27 | Сайдекс, Инк. (Us) | Препаративная форма для ингалятора сухого порошка, содержащая простой сульфоалкиловый эфир циклодекстрина |
| CA2565980A1 (en) | 2004-05-12 | 2005-12-01 | Luca Technologies, Llc | Generation of hydrogen from hydrocarbon-bearing materials |
| US7426960B2 (en) | 2005-05-03 | 2008-09-23 | Luca Technologies, Inc. | Biogenic fuel gas generation in geologic hydrocarbon deposits |
| US20100204178A1 (en) | 2006-10-02 | 2010-08-12 | James Cloyd | Novel parenteral carbamazepine formulation |
| US7629331B2 (en) | 2005-10-26 | 2009-12-08 | Cydex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof |
| US7416879B2 (en) | 2006-01-11 | 2008-08-26 | Luca Technologies, Inc. | Thermacetogenium phaeum consortium for the production of materials with enhanced hydrogen content |
| WO2007112274A2 (en) | 2006-03-28 | 2007-10-04 | Javelin Pharmaceuticals, Inc. | Formulations of low dose non-steroidal anti-inflammatory drugs and beta-cyclodextrin |
| KR20150050595A (ko) | 2006-03-28 | 2015-05-08 | 자블린 파머슈티칼스 인코포레이티드 | 저 복용량의 디클로페낙 및 베타-사이클로덱스트린 제형 |
| US7696132B2 (en) * | 2006-04-05 | 2010-04-13 | Luca Technologies, Inc. | Chemical amendments for the stimulation of biogenic gas generation in deposits of carbonaceous material |
| US7977282B2 (en) | 2006-04-05 | 2011-07-12 | Luca Technologies, Inc. | Chemical amendments for the stimulation of biogenic gas generation in deposits of carbonaceous material |
| US20090239942A1 (en) * | 2006-09-15 | 2009-09-24 | Cloyd James C | Topiramate Compositions and Methods of Making and Using the Same |
| US20080194519A1 (en) * | 2006-09-15 | 2008-08-14 | Regents Of The University Of Minnesota | Topiramate compositions and methods for their use |
| US20090270496A1 (en) * | 2007-05-03 | 2009-10-29 | Courchesne William E | Antifungal compounds |
| US7635773B2 (en) | 2008-04-28 | 2009-12-22 | Cydex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin compositions |
| US8479813B2 (en) | 2009-12-16 | 2013-07-09 | Luca Technologies, Inc. | Biogenic fuel gas generation in geologic hydrocarbon deposits |
| EP2335686A1 (en) | 2009-12-21 | 2011-06-22 | LEK Pharmaceuticals d.d. | An aqueous intravenous nanosuspension with reduced adverse effects |
| NL2004260C2 (en) * | 2010-02-18 | 2011-08-22 | Univ Amsterdam | Disinfectant composition and its use in dental treatment. |
| WO2011156481A2 (en) | 2010-06-11 | 2011-12-15 | Baxter International Inc. | Formulations including amiodarone and salts thereof and methods of their manufacture and use |
| US20140221490A1 (en) | 2011-07-20 | 2014-08-07 | Hospira, Inc. | Methods of treating pain |
| CA2852716C (en) | 2011-11-29 | 2015-11-17 | Jurox Pty Ltd | Methods of preserving injectable pharmaceutical compositions comprising a cyclodextrin and a hydrophobic drug |
| EP3415153A1 (en) * | 2012-01-30 | 2018-12-19 | Baxalta GmbH | Non-anticoagulant sulfated or sulfonated polysaccharides |
| DK2814849T3 (da) | 2012-02-15 | 2020-03-09 | Cydex Pharmaceuticals Inc | Fremgangsmåde til fremstilling af cyclodextrin-derivater |
| KR101633479B1 (ko) | 2012-02-28 | 2016-07-08 | 사이덱스 파마슈티칼스, 인크. | 알킬화된 시클로덱스트린 조성물 및 이의 제조 및 사용 방법 |
| US9004162B2 (en) | 2012-03-23 | 2015-04-14 | Transworld Technologies Inc. | Methods of stimulating acetoclastic methanogenesis in subterranean deposits of carbonaceous material |
| US20150258202A1 (en) * | 2012-10-17 | 2015-09-17 | Sapiotec Gmbh | Anthocyanidin complex for the treatment of multiple myeloma |
| MX360192B (es) | 2012-10-22 | 2018-10-24 | Cydex Pharmaceuticals Inc | Composiciones de ciclodextrinas alquiladas y procesos para preparar y usar las mismas. |
| US9925274B2 (en) * | 2012-11-15 | 2018-03-27 | Sapiotec Gmbh | Delphinidin complex as an antiphlogistic or immunosuppressive active ingredient |
| EP2773033B1 (en) | 2013-02-28 | 2018-12-05 | Dialog Semiconductor GmbH | Divide by 2 and 3 charge pump methods |
| GB201312737D0 (en) | 2013-07-17 | 2013-08-28 | Univ Greenwich | Cyclodextrin |
| US10851184B2 (en) | 2014-08-22 | 2020-12-01 | Cydex Pharmaceuticals, Inc. | Fractionated alkylated cyclodextrin compositions and processes for preparing and using the same |
| US10736891B2 (en) | 2016-01-07 | 2020-08-11 | Roy MADIGAN | Composition and method for treating chagas disease |
| WO2017149552A1 (en) * | 2016-03-04 | 2017-09-08 | Sun Pharmaceutical Industries Ltd. | Parenteral dosage form of amiodarone |
| CN107753439A (zh) * | 2016-08-22 | 2018-03-06 | 黑龙江迪龙制药有限公司 | 一种注射用盐酸胺碘酮及其制备方法 |
| EP3541364A1 (en) | 2016-11-18 | 2019-09-25 | AiCuris Anti-infective Cures GmbH | Novel formulations of amidine substituted beta-lactam compounds on the basis of modified cyclodextrins and acidifying agents, their preparation and use as antimicrobial pharmaceutical compositions |
| EP3968979A4 (en) * | 2019-05-15 | 2023-03-01 | Bexson Biomedical, Inc. | KETAMINE FORMULATION FOR SUBCUTANEOUS INJECTION |
| US20230000997A1 (en) | 2019-08-06 | 2023-01-05 | L.E.A.F. Holdings Group Llc | Processes of preparing polyglutamated antifolates and uses of their compositions |
| CN115969833A (zh) * | 2023-01-03 | 2023-04-18 | 上海上药第一生化药业有限公司 | 胺碘酮药物组合物、注射液及其制备方法及含其的注射器 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991004026A1 (en) | 1989-09-14 | 1991-04-04 | Australian Commercial Research & Development Limited | Drug delivery compositions |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| KR0166088B1 (ko) * | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| WO1991013100A1 (en) | 1990-03-02 | 1991-09-05 | Australian Commercial Research & Development Limited | Cyclodextrin compositions and methods for pharmaceutical and industrial applications |
| US5234949A (en) | 1992-04-01 | 1993-08-10 | Academic Pharmaceuticals, Inc. | Parenteral solutions containing amiodarone in acetate buffer solution |
| FR2735978B1 (fr) * | 1995-06-30 | 1997-09-19 | Sanofi Sa | Composition pharmaceutique d'amiodarone pour administration parenterale |
| UA57734C2 (uk) * | 1996-05-07 | 2003-07-15 | Пфайзер Інк. | Комплекси включення арилгетероциклічних солей |
| US5916883A (en) * | 1996-11-01 | 1999-06-29 | Poly-Med, Inc. | Acylated cyclodextrin derivatives |
| US6046177A (en) * | 1997-05-05 | 2000-04-04 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations |
| US5874418A (en) * | 1997-05-05 | 1999-02-23 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use |
| NZ511995A (en) * | 1999-01-21 | 2003-11-28 | Bristol Myers Squibb Co | A ras-farnesyltransferase inhibitor complex that is stable and water soluble and useful as an anti-tumour agent |
| US6267985B1 (en) | 1999-06-30 | 2001-07-31 | Lipocine Inc. | Clear oil-containing pharmaceutical compositions |
| US6294192B1 (en) | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
| GB9921958D0 (en) * | 1999-09-16 | 1999-11-17 | Pharmacia & Upjohn Spa | Formulations for parenteral use of estramustine phosphate and sulfoalkylether-cyclodextrins |
| US6479541B1 (en) * | 2000-03-30 | 2002-11-12 | Baxter International | Amiodarone-containing parenteral administration |
-
2002
- 2002-05-04 US US10/139,620 patent/US6869939B2/en not_active Expired - Lifetime
-
2003
- 2003-04-29 MX MXPA04010925A patent/MXPA04010925A/es active IP Right Grant
- 2003-04-29 KR KR1020047017639A patent/KR100984197B1/ko active IP Right Grant
- 2003-04-29 JP JP2004500775A patent/JP4764004B2/ja not_active Expired - Lifetime
- 2003-04-29 CA CA2483774A patent/CA2483774C/en not_active Expired - Lifetime
- 2003-04-29 EP EP11182697.0A patent/EP2402008B1/en not_active Expired - Lifetime
- 2003-04-29 PT PT03728598T patent/PT1501496E/pt unknown
- 2003-04-29 WO PCT/US2003/013250 patent/WO2003092590A2/en active Application Filing
- 2003-04-29 AT AT03728598T patent/ATE535239T1/de active
- 2003-04-29 IL IL16502203A patent/IL165022A0/xx unknown
- 2003-04-29 AU AU2003234285A patent/AU2003234285B2/en not_active Expired
- 2003-04-29 SI SI200332113T patent/SI1501496T1/sl unknown
- 2003-04-29 DK DK11182697.0T patent/DK2402008T3/en active
- 2003-04-29 ES ES03728598T patent/ES2378306T3/es not_active Expired - Lifetime
- 2003-04-29 SI SI200332474A patent/SI2402008T1/sl unknown
- 2003-04-29 EP EP03728598A patent/EP1501496B1/en not_active Expired - Lifetime
- 2003-04-29 DK DK03728598.8T patent/DK1501496T3/da active
- 2003-04-29 ES ES11182697.0T patent/ES2567716T3/es not_active Expired - Lifetime
- 2003-04-29 HU HUE11182697A patent/HUE027551T2/en unknown
-
2004
- 2004-11-04 IL IL165022A patent/IL165022A/en active IP Right Grant
-
2011
- 2011-03-07 JP JP2011048873A patent/JP5656692B2/ja not_active Expired - Lifetime
-
2012
- 2012-02-23 CY CY20121100190T patent/CY1112527T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CY1112527T1 (el) | 2015-12-09 |
| EP1501496A2 (en) | 2005-02-02 |
| JP2011116776A (ja) | 2011-06-16 |
| IL165022A (en) | 2011-08-31 |
| ES2567716T3 (es) | 2016-04-26 |
| KR20040106452A (ko) | 2004-12-17 |
| SI1501496T1 (sl) | 2012-04-30 |
| EP1501496B1 (en) | 2011-11-30 |
| DK1501496T3 (da) | 2012-03-19 |
| US20030216353A1 (en) | 2003-11-20 |
| WO2003092590A2 (en) | 2003-11-13 |
| JP2005530744A (ja) | 2005-10-13 |
| US6869939B2 (en) | 2005-03-22 |
| CA2483774C (en) | 2011-07-19 |
| MXPA04010925A (es) | 2005-02-14 |
| EP2402008B1 (en) | 2016-01-27 |
| EP2402008A1 (en) | 2012-01-04 |
| JP4764004B2 (ja) | 2011-08-31 |
| HUE027551T2 (en) | 2016-10-28 |
| JP5656692B2 (ja) | 2015-01-21 |
| AU2003234285B2 (en) | 2007-01-04 |
| ATE535239T1 (de) | 2011-12-15 |
| DK2402008T3 (en) | 2016-05-02 |
| AU2003234285A1 (en) | 2003-11-17 |
| KR100984197B1 (ko) | 2010-09-28 |
| SI2402008T1 (sl) | 2016-05-31 |
| PT1501496E (pt) | 2012-02-20 |
| WO2003092590A3 (en) | 2004-01-22 |
| EP1501496A4 (en) | 2006-05-31 |
| CA2483774A1 (en) | 2003-11-13 |
| ES2378306T3 (es) | 2012-04-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL165022A (en) | Formulations containing amiodarone and sulfoalkyl ether cyclodextrin | |
| IL154888A (en) | Aqueous Pharmaceutical Gel Preparation Containing At least One Vitamin D or One Vitamin D Analog At least One Corticosteroid | |
| AU2002325856A1 (en) | Agent containing fat (oil), which contains onion extract, the production and use thereof for caring, preventing or treating damaged skin tissue, especially scarred tissue | |
| EP1435894A4 (en) | CYTOPROTECTIVE COMPOUNDS, METHODS AND PHARMACEUTICAL AND COSMETIC FORMULATIONS | |
| WO2003028802A3 (en) | Devices for treating atrial fibrilation | |
| PL1643833T3 (pl) | Formulacje agrochemiczne | |
| HK1078466A1 (en) | Treatment of affective disorders by the combined action of a nicotinic ; receptor agonist and a monoaminergic substance | |
| MXPA05013232A (es) | Composicion en forma de pulverizador que comprende un activo farmaceutico, al menos una silicona volatil y una fase aceitosa no volatil. | |
| IL216579A0 (en) | Aminocyclohexyl ether derivatives and pharmaceutical compositions containing the same | |
| WO2001078702A3 (en) | Methods and compositions for modulating alpha adrenergic receptor activity | |
| HUP0204399A3 (en) | Pteridine compounds for the treatment of psoriasis, process for their preparation, pharmaceutical compositions containing them and their use | |
| WO2001015715A3 (en) | Composition for maintenance of bone or dental health or treatment of bone or dental disorders | |
| CY1107942T1 (el) | Ψεκασιμη συνθεση για τη χορηγηση παραγωγων της βιταμινης d | |
| PL1654253T3 (pl) | Podstawione pochodne 3-pirolidynoindolu | |
| EP1259240B8 (en) | Agents, such as nicotinamide or cadpr for the treatment of skin disorders | |
| IL172423A0 (en) | Novel formulations for opioid -based treatments of pain comprising substituted 1,4-di-piperidin-4-yl-piperazine derivatives | |
| HK1040983A1 (en) | Quinones for treatment of diseases. | |
| EP1248792A4 (en) | ANTISENSE MODULATION OF GAMMA RECEPTOR ACTIVE PEROXYSOME PROLIFERATION (PPAR) EXPRESSION | |
| WO2005046599A3 (en) | Alpha, beta-unsaturated sulfoxides for treating proliferative disorders | |
| WO2004098522A3 (en) | Gemini vitamin d3 compounds and methods of use thereof | |
| NO20060655L (no) | 2-alkyliden-19-Nor-vitamin D derivater for behandling av osteofeni eller osteoporose hos hannkjonn | |
| HK1065305A1 (en) | Substituted 4-aminocyclohexanol derivatives | |
| IL150527A0 (en) | Use of vitamin d-derivatives in the treatment of osteoporosis and related bone disorders, as well as novel vitamin d3-derivatives | |
| MXPA03006626A (es) | Formulacion de la goma para el tratamiento de la semilla de plantas. | |
| AU2002235202A1 (en) | Treatment of bone disorders by modulation of fgfr3 |